Valneva SE AYJ.F Stock
Valneva SE Price Chart
Valneva SE AYJ.F Financial and Trading Overview
Valneva SE stock price | 4.01 EUR |
Previous Close | 6.67 EUR |
Open | 6.66 EUR |
Bid | 6.81 EUR x 250000 |
Ask | 6.87 EUR x 250000 |
Day's Range | 6.66 - 6.81 EUR |
52 Week Range | 3.97 - 15.2 EUR |
Volume | 300 EUR |
Avg. Volume | 4K EUR |
Market Cap | 945.04M EUR |
Beta (5Y Monthly) | 0.899233 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.73 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
AYJ.F Valuation Measures
Enterprise Value | 832.48M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.5338566 |
Price/Book (mrq) | 4.6358066 |
Enterprise Value/Revenue | 2.232 |
Enterprise Value/EBITDA | -8.431 |
Trading Information
Valneva SE Stock Price History
Beta (5Y Monthly) | 0.899233 |
52-Week Change | -15.55% |
S&P500 52-Week Change | 20.43% |
52 Week High | 15.2 EUR |
52 Week Low | 3.97 EUR |
50-Day Moving Average | 5.26 EUR |
200-Day Moving Average | 6.18 EUR |
AYJ.F Share Statistics
Avg. Volume (3 month) | 4K EUR |
Avg. Daily Volume (10-Days) | 4.2K EUR |
Shares Outstanding | 138.77M |
Float | 93.13M |
Short Ratio | N/A |
% Held by Insiders | 17.56% |
% Held by Institutions | 21.36% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -36.29% |
Operating Margin (ttm) | -29.96% |
Gross Margin | -15.12% |
EBITDA Margin | -26.47% |
Management Effectiveness
Return on Assets (ttm) | -10.21% |
Return on Equity (ttm) | -76.65% |
Income Statement
Revenue (ttm) | 372.96M EUR |
Revenue Per Share (ttm) | 3.03 EUR |
Quarterly Revenue Growth (yoy) | 53.40% |
Gross Profit (ttm) | -68060000 EUR |
EBITDA | -98744000 EUR |
Net Income Avi to Common (ttm) | -135364992 EUR |
Diluted EPS (ttm) | -1.2 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 254.48M EUR |
Total Cash Per Share (mrq) | 1.83 EUR |
Total Debt (mrq) | 152.73M EUR |
Total Debt/Equity (mrq) | 74.58 EUR |
Current Ratio (mrq) | 1.479 |
Book Value Per Share (mrq) | 1.469 |
Cash Flow Statement
Operating Cash Flow (ttm) | -242818000 EUR |
Levered Free Cash Flow (ttm) | -143397504 EUR |
Profile of Valneva SE
Country | Germany |
State | N/A |
City | Saint-Herblain |
Address | 6 rue Alain Bombard |
ZIP | 44800 |
Phone | 33 2 28 07 37 10 |
Website | https://valneva.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 719 |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.
Q&A For Valneva SE Stock
What is a current AYJ.F stock price?
Valneva SE AYJ.F stock price today per share is 4.01 EUR.
How to purchase Valneva SE stock?
You can buy AYJ.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Valneva SE?
The stock symbol or ticker of Valneva SE is AYJ.F.
Which industry does the Valneva SE company belong to?
The Valneva SE industry is Biotechnology.
How many shares does Valneva SE have in circulation?
The max supply of Valneva SE shares is 139.29M.
What is Valneva SE Price to Earnings Ratio (PE Ratio)?
Valneva SE PE Ratio is now.
What was Valneva SE earnings per share over the trailing 12 months (TTM)?
Valneva SE EPS is -0.73 EUR over the trailing 12 months.
Which sector does the Valneva SE company belong to?
The Valneva SE sector is Healthcare.